NASDAQ · MYGN
Myriad Genetics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MYGN: Nov 04, 2026
Myriad Genetics, Inc. Common Stock is expected to report earnings on 11/04/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.25. The reported EPS for the same quarter last year was $-0.13.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.25 | $-0.24 | $-0.25 | 2 |
| Dec 2026 | $-0.25 | $-0.23 | $-0.28 | 2 |
| Mar 2027 | $-0.23 | $-0.23 | $-0.23 | 1 |
| Jun 2027 | $-0.24 | $-0.24 | $-0.24 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · BNK Invest- Fintel · Oct 23, 9:13 PM EDTMyriad Genetics Consensus Price Target Increased by 33.29% to $4.58The average one-year price target for Myriad Genetics (NASDAQGS:MYGN) (DB:MYD) has been revised to $4.58 / share. This is an increase of 33.29% from the prior estimate of $3.43 dated September 29, 2026. These figures represent aggregate analyst targets and do not constitute a rec
- RTTNews · Oct 22, 2:08 PM EDTMyriad Genetics Reports New MRD Detection Data In Colorectal And Pancreatic Cancers(RTTNews) – Myriad Genetics (MYGN) announced new data from the ongoing MONSTAR-SCREEN-3 study demonstrating the potential of its whole-genome sequencing-based Precise MRD platform to detect molecular residual disease (MRD) and identify recurrence risk in patients with resectable
- RTTNews · Oct 20, 2:49 PM EDTBiotech Stocks Move Higher: MBRX Gains 15%, FEMY Rises 7%, RVMD Advances 7%, MYGN Surges Over 40%(RTTNews) – Correction: The earlier fact provided in "This Day in History" was incorrect. It has been updated with the correct information.
- BNK Invest · Oct 20, 12:25 PM EDTTuesday's ETF Movers: XBI, CRAKIn trading on Tuesday, the State Street SPDR S&P Biotech ETF is outperforming other ETFs, up about 3.5% on the day. Components of that ETF showing particular strength include shares of Myriad Genetics, up about 37.5% and shares of Sagimet Biosciences, up about 12.4% on the
- BNK Invest · Oct 20, 12:24 PM EDTTuesday Sector Leaders: Biotechnology, DrugsIn trading on Tuesday, biotechnology shares were relative leaders, up on the day by about 4.2%. Leading the group were shares of Myriad Genetics, up about 37.5% and shares of Larimar Therapeutics up about 14.4% on the day. Also showing relative strength are drugs shares, up on
- RTTNews · Oct 20, 10:09 AM EDTMyriad Genetics Surge On $210 Mln Prenatal Testing Business Sale To Labcorp(RTTNews) – Myriad Genetics, Inc. (MYGN), a molecular diagnostic testing and precision medicine company, has entered into a definitive agreement to sell its Prenatal Health testing business to Labcorp Holdings Inc.(LH) for $210 million in cash, plus the value of inventory at clos
- RTTNews · Oct 20, 9:38 AM EDTLabcorp To Buy Myriad Genetics' Prenatal Testing Business For $210 Mln(RTTNews) – Laboratory services provider LabCorp Holdings Inc. (LH) announced on Tuesday that it has agreed to acquire the Prenatal Health testing business of molecular diagnostics company Myriad Genetics Inc. (MYGN) for $210 million in cash, plus the value of inventory at closin
- RTTNews · Oct 9, 1:37 PM EDTWeekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data(RTTNews) – This week, biopharmaceutical companies saw a busy week of regulatory decisions, strategic partnerships and clinical developments, alongside pipeline setbacks and workforce reductions.
- RTTNews · Oct 8, 10:50 AM EDTMyriad Genetics, SOPHiA GENETICS Partner With AstraZeneca On Prostate Cancer PrGIS(RTTNews) – Myriad Genetics (MYGN) and SOPHiA GENETICS (SOPH) announced a collaboration with AstraZeneca (AZN) to advance a new prostate cancer-specific genomic instability score, or PrGIS, for precision oncology.
- RTTNews · Oct 8, 9:29 AM EDTSOPHiA GENETICS Partners Myriad Genetics To Advance Prostate Genomic Instability Score Technology(RTTNews) – SOPHiA GENETICS (SOPH) and Myriad Genetics, Inc. (MYGN) announced Thursday a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (AZN).
- RTTNews · Sep 16, 11:00 AM EDTMyriad Genetics Names Sikri Commercial EVP; Reaffirms 2026 Guidance(RTTNews) – Myriad Genetics, Inc. (MYGN) announced that Vishal Sikri has been promoted to Executive Vice President – Commercial, effective September 16, 2026.
- BNK Invest · Sep 11, 6:46 AM EDTMyriad Genetics Reaches Analyst Target PriceIn recent trading, shares of Myriad Genetics, Inc. (Symbol: MYGN) have crossed above the average analyst 12-month target price of $3.31, changing hands for $3.36/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Myriad Genetics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.